Drug maker Wockhardt Ltd said on Monday it has inked a strategic pact with US-based Sheffield Bio-Science to supply Wockhardt's recombinant insulin to cell culture markets globally.
Wockhard said Sheffield would have exclusive sales and distribution rights for its recombinant insulin in these markets. It estimated the potential in the cell culture markets at around $50 million.
Wockhardt said it was the first in Asia and the fourth company globally to have developed, manufactured and marketed the recombinant insulin injectables known as Wosulin.
(Reporting by Aniruddha Basu; Editing by Rosemary Arackaparambil)